Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP cut its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 3.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 267,928 shares of the company's stock after selling 9,427 shares during the period. Dimensional Fund Advisors LP owned approximately 0.86% of Medpace worth $89,018,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in Medpace by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company's stock worth $854,087,000 after purchasing an additional 25,704 shares during the last quarter. Invesco Ltd. increased its position in shares of Medpace by 91.8% in the fourth quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock valued at $360,387,000 after buying an additional 519,186 shares in the last quarter. Wasatch Advisors LP raised its stake in shares of Medpace by 3.1% during the 4th quarter. Wasatch Advisors LP now owns 936,842 shares of the company's stock worth $311,247,000 after buying an additional 28,161 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Medpace by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 656,130 shares of the company's stock worth $218,031,000 after buying an additional 28,076 shares in the last quarter. Finally, Bessemer Group Inc. grew its stake in Medpace by 15.0% in the 4th quarter. Bessemer Group Inc. now owns 576,044 shares of the company's stock valued at $191,379,000 after acquiring an additional 75,275 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on MEDP shares. Mizuho cut their target price on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research report on Wednesday, April 9th. Robert W. Baird reduced their target price on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. Leerink Partners started coverage on Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price target for the company. TD Cowen downgraded Medpace from a "buy" rating to a "hold" rating and reduced their price objective for the company from $370.00 to $328.00 in a research report on Monday, April 14th. Finally, William Blair reiterated a "market perform" rating on shares of Medpace in a research report on Tuesday, April 22nd. Eleven research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, Medpace presently has a consensus rating of "Hold" and an average price target of $349.30.

Insiders Place Their Bets

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of the company's stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the sale, the director now directly owns 2,998 shares of the company's stock, valued at approximately $904,856.36. This represents a 36.35 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 20.30% of the stock is currently owned by insiders.

Medpace Stock Up 0.9 %

Shares of MEDP traded up $2.86 during mid-day trading on Friday, hitting $305.11. The company had a trading volume of 313,502 shares, compared to its average volume of 342,098. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $459.77. The business's 50-day simple moving average is $310.62 and its 200-day simple moving average is $330.57. The stock has a market cap of $8.77 billion, a PE ratio of 24.16, a P/E/G ratio of 3.81 and a beta of 1.46.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. The company had revenue of $558.57 million for the quarter, compared to analyst estimates of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same quarter last year, the business earned $3.20 EPS. On average, sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.